No abstract

Metal–organic frameworks (MOFs), as a prominent category of hybrid porous materials, have been broadly employed as controlled systems of drug delivery due to their inherent interesting properties.

An investigation was conducted to evaluate the ability of Deferasirox (ICL670 or Exjade) following the distribution of cadmium salt in male Wistar rats. Cadmium was introduced to several groups of weanling male Wistar rats through different means, by act of drinking, feeding. A control group was fed on a diet containing normal level of iron. After a period of 30 days, all the rats administered cadmium were severely anemic and showed toxicity symptoms through loss of hair and increasing in cadmium and reduction in iron levels in blood. Chelation therapy was carried out to remove the toxic element from the body. The ability of Deferasirox chelator in removing cadmium was investigated this chelator for 1 week to the remaining rats of similar groups. The results showed that the cadmium level present in blood was significantly reduced and at the same time, iron concentration returned to the normal level. It was concluded that Deferasirox chelator is able to remove cadmium from the body and could be used for the treatment of complications and eradication of symptoms of cadmium intoxication.

The importance of early-stage diagnosis and in situ monitoring of lesion regions and transportation of bioactive molecules has a pivotal effect on the successful treatment, reducing side effects, and increasing...

Investigations were conducted to evaluate the ability of two chelators, desferrioxamine (DFO), and deferiprone (1,2-dimethy1-3-hydroxypyride-4-one, L 1 ), for the excretion of vanadium after a period of administration of vanadium salts in 6-week-old male Wistar rats. Immediately after 60 days of vanadium administration, the rats received chelators (L 1 , DFO or L 1 ? DFO) for a period of 1 week. Chelators were given orally (L 1 ), intraperitoneally (DFO), or both to different groups of rats at two different dosage levels. After chelation therapy, animals were sacrificed by exsanguination from abdominal aorta. Blood, kidney, liver, and heart samples were collected and prepared for determination of vanadium and iron concentrations by graphite furnace and flame atomic absorption spectroscopy (GF AAS, and F AAS) methods, respectively. These chelators significantly enhanced the urinary and biliary excretion of vanadium and restored the altered levels of iron. Furthermore, the hypothesis that these two known chelators might be more effective in removing vanadium from the body as a combined treatment than as monotherapy also was tested in this study. Although there is no significant difference between these two chelators in reducing the vanadium concentration, combination therapy (L 1 ? DFO) may cause higher efficacy and lower toxicity compared with monotherapies. Collectively, the results indicate that the designed procedure might be useful for preliminary in vivo testing of the efficiency of a chelating agent. However, our findings regarding the efficacy of combination therapy should be confirmed in more experiments. This preliminary study does not provide all answers to the magnitude of the efficiency of chelating agents in vanadium toxicity, and thus, further research is warranted.